ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

Eli Lilly shared early clinical data on the BTK inhibitor it acquired with Loxo Oncology—and the numbers have Lilly outlining plans for “an ambitious comprehensive development program."